Showing results (1-10 of 663) with videos related to
Sort By:
Pageof 67
Clinical Pharmacology and Therapeutics|January 1, 1990
Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronideR Osborne, S Joel, D Trew, et al.Clinical Pharmacology and Therapeutics|August 1, 1993
The pharmacokinetics of morphine and morphine glucuronides in kidney failureR Osborne, S Joel, K Grebenik, et al.British Journal of Clinical Pharmacology|August 1, 1992
The analgesic activity of morphine-6-glucuronideR Osborne, P Thompson, S Joel, et al.Cancer Chemotherapy and Pharmacology|January 1, 1987
High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancerR Osborne, B Evans, C Gallagher, et al.British Journal of Cancer|May 1, 1993
A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexiaS Downer, S Joel, A Allbright, et al.British Journal of Cancer|January 1, 1997
Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology GroupsM E Gore, G Rustin, M Slevin, et al.British Journal of Cancer|January 1, 1997
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacyP N Mainwaring, M C Nicolson, T Hickish, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancerS Joel, K O'Byrne, R Penson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology GroupM Gore, P Mainwaring, R A'Hern, et al.Histology and Histopathology|September 18, 2009
A role for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease?M Slevin, J KrupinskiPageof 67